Skip Navigation

Publication Detail

Title: Eicosanoids: The Overlooked Storm in Coronavirus Disease 2019 (COVID-19)?

Authors: Hammock, Bruce D; Wang, Weicang; Gilligan, Molly M; Panigrahy, Dipak

Published In Am J Pathol, (2020 09)

Abstract: Severe coronavirus disease 2019 (COVID-19) symptoms, including systemic inflammatory response and multisystem organ failure, are now affecting thousands of infected patients and causing widespread mortality. Coronavirus infection causes tissue damage, which triggers the endoplasmic reticulum stress response and subsequent eicosanoid and cytokine storms. Although proinflammatory eicosanoids, including prostaglandins, thromboxanes, and leukotrienes, are critical mediators of physiological processes, such as inflammation, fever, allergy, and pain, their roles in COVID-19 are poorly characterized. Arachidonic acid-derived epoxyeicosatrienoic acids could alleviate the systemic hyperinflammatory response in COVID-19 infection by modulating endoplasmic reticulum stress and stimulating the resolution of inflammation. Soluble epoxide hydrolase (sEH) inhibitors, which increase endogenous epoxyeicosatrienoic acid levels, exhibit potent anti-inflammatory activity and inhibit various pathologic processes in preclinical disease models, including pulmonary fibrosis, thrombosis, and acute respiratory distress syndrome. Therefore, targeting eicosanoids and sEH could be a novel therapeutic approach in combating COVID-19. In this review, we discuss the predominant role of eicosanoids in regulating the inflammatory cascade and propose the potential application of sEH inhibitors in alleviating COVID-19 symptoms. The host-protective action of omega-3 fatty acid-derived epoxyeicosanoids and specialized proresolving mediators in regulating anti-inflammation and antiviral response is also discussed. Future studies determining the eicosanoid profile in COVID-19 patients or preclinical models are pivotal in providing novel insights into coronavirus-host interaction and inflammation modulation.

PubMed ID: 32650004 Exiting the NIEHS site

MeSH Terms: Animals; Anti-Inflammatory Agents/pharmacology*; Betacoronavirus/drug effects*; Betacoronavirus/pathogenicity; COVID-19; Coronavirus Infections/drug therapy*; Eicosanoids/pharmacology; Eicosanoids/therapeutic use; Endoplasmic Reticulum Stress/drug effects; Humans; Pandemics; Pneumonia, Viral/drug therapy*; SARS-CoV-2

to Top